Aegerion Pharmaceuticalsestablished In 2005 And Based In Cambridgemassachusettsis A Biopharmaceutical Company Focused On Developing And Commercializing Therapies For Rare Diseasesparticularly Cardiovascular And Metabolic Disordersthe Company Serves The Healthcare Sectorincluding Hospitals And Clinicsby Providing Innovative Treatments For Rare And Debilitating Conditions Aegerion Is Known For Its Product Juxtapidlomitapide Which Treats Homozygous Familial Hypercholesterolemiahofh A Rare Genetic Disorder That Leads To High Ldl Cholesterol Levelsjuxtapid Is An Oral Medication That Complements A Low Fat Diet And Other Lipid Lowering Treatmentsanother Significant Product Is Myaleptmetreleptin A Leptin Replacement Therapy For Generalized Lipodystrophya Condition Marked By A Deficiency Of Leptin In July 2022Aegerion Pharmaceuticals Increbranded As Amryt Pharmaceuticals Incand Now Operates As A Subsidiary Of Amryt Pharma Holdings Limitedreflecting A Strategic Shift In Its Operations And Branding
